Tag - daiichi-sankyo

 
Menu
Search
 
April 24, 2024
 

Today's print edition

Home Delivery
Subscribe for more access

DAIICHI SANKYO

Prime Minister Fumio Kishida receives a COVID-19 booster shot in Tokyo on Nov. 11.
JAPAN / Science & Health
Nov 28, 2023
Japan approves first domestically developed COVID-19 XBB vaccine
The XBB-adapted coronavirus vaccine will be available as a booster under the nation’s free COVID-19 vaccination program beginning next week.
Daiichi Sankyo is aiming for at least ¥900 billion of revenue from its oncology business in the fiscal year ending in March 2026.
BUSINESS
Oct 20, 2023
Merck signs $5.5 billion deal with Daiichi for cancer therapy development
Daiichi Sankyo is aiming for at least ¥900 billion of revenue from its oncology business in the fiscal year ending in March 2026.
A health ministry panel has approved the messenger RNA vaccine Daichirona.
JAPAN / Science & Health
Aug 1, 2023
Japan panel endorses first domestically developed COVID vaccine
The shot is based on the original strain of the coronavirus, making it unlikely that it will be used in Japan or elsewhere.
Japan Times
BUSINESS / Companies
Jun 7, 2023
AstraZeneca’s Japan partner to go solo on future cancer drugs
Daiichi Sankyo is expanding its sales and development staff overseas, aiming to boost production capacity so that it can handle its cancer drugs business entirely on its own.
Japan Times
BUSINESS
Jan 13, 2023
Japan's Daiichi Sankyo applies for approval of mRNA COVID vaccine
An approval would give Japan a homegrown mRNA vaccine — a vaccine type that has played a dominant role in the country's COVID-19 inoculation drive to this point.
Japan Times
JAPAN / Science & Health
Nov 15, 2022
Japan's Daiichi Sankyo says mRNA COVID vaccine successful in booster trial
Approval would give Japan a home-grown source for mRNA vaccines, which have made up the bulk of its COVID-19 inoculations to date.
Japan Times
COMMENTARY / World
Jun 8, 2022
The drug that could transform breast cancer treatment
The early success of Enhertu, from AstraZeneca and Daiichi Sankyo, bodes well for an entire class of medicines that may one day replace conventional chemotherapy.
Japan Times
BUSINESS
Dec 27, 2021
Tardy COVID-19 vaccine makers under fire for trials in developing nations
Vaccine developers at the testing phase now are seeking developing countries where vaccination rates remain low and the virus is still active.
Japan Times
BUSINESS / Companies
Sep 6, 2021
Daiichi Sankyo positions its COVID-19 vaccine as a booster in Japan
Daiichi Sankyo is aiming for full regulatory approval by the second half of next year.
Japan Times
JAPAN / Science & Health
Mar 23, 2021
Japanese firms launch domestic clinical trials for COVID-19 vaccines
Even as Daiichi Sankyo and KM Biologics begin work to prove their shots' efficacy and safety, the public is unlikely to have access to them until fiscal 2022 at the earliest.
Japan Times
JAPAN
Mar 12, 2021
Japanese drugmaker starts AstraZeneca vaccine production
Daiichi Sankyo Co. on Thursday began the vial filling and packaging of the vaccine using undiluted solutions provided by AstraZeneca.
JAPAN / Science & Health
Aug 31, 2020
Daiichi Sankyo's COVID-19 vaccine candidate selected by Japanese drug discovery body
Daiichi Sankyo Co. said on Monday that its mRNA-based COVID-19 vaccine candidate was selected for inclusion in a drug discovery program by the Japan Agency for Medical Research and Development.
Japan Times
BUSINESS / Companies
Jul 28, 2020
Astra to pay Daiichi up to $6 billion for new cancer drug
AstraZeneca is forging ahead to become a global oncology powerhouse, even as it works on a vaccine for the coronavirus pandemic.
Japan Times
JAPAN / Science & Health
Jun 12, 2020
Daiichi Sankyo sees clinical test for genetic COVID-19 vaccine in March
The vaccine contains messenger RNA that causes cells to produce proteins that could trigger the body to produce effective antibodies.
Japan Times
JAPAN / Science & Health
Jun 16, 2019
Drug devised to replace chemotherapy may reshape cancer care
A class of drugs is emerging that can attack cancer cells in the body without damaging surrounding healthy ones. They have the potential to replace chemotherapy and its disruptive side effects, reshaping the future of cancer care.
Japan Times
BUSINESS / Companies
Mar 29, 2019
AstraZeneca bets $6.9 billion that Daiichi Sankyo therapy will transform cancer treatment
Britain's AstraZeneca's biggest deal in recent memory give it access to the Japanese drugmaker's promising but difficult to pronounce cancer treatment: trastuzumab deruxtecan.
Japan Times
BUSINESS / Companies
Sep 29, 2017
Opioids demand rises in Japan as seniors use drugs to ease pain and improve quality of life
Selling painkillers in Japan used to be like pulling teeth. That was until baby boomers discovered how analgesics could take the sting from arthritis, diabetic nerve damage and the ravages of cancer.
Japan Times
BUSINESS / Companies
Aug 2, 2017
Daiichi Sankyo settles U.S. lawsuits over intestinal damage from blood-pressure drugs, paying $300 million
Daiichi Sankyo Inc. has settled thousands of lawsuits alleging its blood-pressure drugs caused intestinal damage, bringing to $339 million the amount the drugmaker has paid over the medicines.
BUSINESS / Companies
May 6, 2016
Daiichi Sankyo awarded damages over cover-up at Indian ex-subsidiary
Daiichi Sankyo Co. said Friday that an international arbitration court has ordered former shareholders of an Indian firm it acquired in 2008 to pay the drugmaker around ¥56.2 billion ($524 million) for concealing critical information.
Japan Times
BUSINESS / Companies
Feb 9, 2015
Growth concerns loom for Daiichi Sankyo on drug warning
Daiichi Sankyo Co. risks losing a slice of revenue to generic-medicine competition next year. Now, the drugmaker's plans to fill the gap have hit a roadblock and investors worry that growth may flounder.
'Sugar Baby Riri' gets nine-year prison term over romance scam
Mai Watanabe, who went by the moniker “Sugar Baby Riri,” dated older men and swindled them out of money by telling them fictitious heartbreaking stories about herself to gain their sympathy.
Japan’s cannabis market growing rapidly amid regulatory shift
The legality of products that contain cannabinoids, a group of substances derived from the cannabis plant, has been somewhat murky in Japan.
The story isn't over for Japan's bookstores
Later this month, author Shogo Imamura will open Honmaru, a bookstore that allows other businesses to rent its shelves. It's part of a wave of ideas Japanese booksellers are trying to compete with online spaces.
Hybrid work takes root in Japan, survey finds
A dealer works in the trading room at a foreign exchange brokerage in Tokyo on March 28. An overwhelming majority of respondents who currently work remotely in some capacity say they wish to continue to do so.
Shohei Ohtani signs deal with sports technology company Rapsodo
Shohei Ohtani has been appointed as the new technology ambassador for Rapsodo, the company announced Monday.
A craft beer crawl through Tokyo’s top bars, brewpubs and dives
If all you drink is Asahi, Sapporo and Kirin, you're depriving yourself of some of the best craft beer Tokyo has to offer — and there sure is a lot of it out there.
'Sugar Baby Riri' gets nine-year prison term over romance scam
Mai Watanabe, who went by the moniker “Sugar Baby Riri,” dated older men and swindled them out of money by telling them fictitious heartbreaking stories about herself to gain their sympathy.
Tsukiji 2030s: A stadium, culinary center and transportation hub
A computer-generated image shows redevelopment plans for the former site of the Tsukiji fish market in Tokyo.
Hearing the impact of climate change in Okinawa, one bird call at a time
Toshihiro Kinjo (center), a research support technician at the Okinawa Institute of Science and Technology, inspects an audio recording device in Ginowan, Okinawa Prefecture, on April 3 as Masako Ogasawara, a research support specialist at OIST, looks on.
Japan’s cannabis market growing rapidly amid regulatory shift
The legality of products that contain cannabinoids, a group of substances derived from the cannabis plant, has been somewhat murky in Japan.

Podcast

From easily navigable train stations to the helpfulness of its municipal staff, Tokyo has earned high praise for its commitment to accessibility for disabled travelers.
[Rebroadcast] Japan is doing better on accessibility than you may think

Longform

Later this month, author Shogo Imamura will open Honmaru, a bookstore that allows other businesses to rent its shelves. It's part of a wave of ideas Japanese booksellers are trying to compete with online spaces.
The story isn't over for Japan's bookstores
By Alex K.T. Martin

SUSTAINABLE JAPAN

Vol. 34: Tokyo, a vanguard city for sustainability
Vol. 34: Tokyo, a vanguard city for sustainability

SPECIAL SUPPLEMENTS note

Read more

SUPPLEMENTS BINDER